We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Drug-Drug Interaction Study of TRK-100STP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00719758
Recruitment Status : Completed
First Posted : July 22, 2008
Last Update Posted : October 13, 2008
Toray Industries, Inc
Information provided by:
Astellas Pharma Inc

Brief Summary:
The purpose of this study is to evaluate the effect of AST-120 on the PK of TRK-100STP, and to evaluate the safety and tolerability of TRK-100STP alone or in combination with AST-120

Condition or disease Intervention/treatment Phase
Healthy Drug: TRK-100STP (BERASUS LA) Drug: AST-120 (Kremezin®) Phase 1

Detailed Description:
Non-blinded, randomized and crossover study to evaluate pharmacokinetic interaction between TRK-100STP and AST-120 in different administration condition. Nonelderly adult volunteers will receive TRK-100STP with or without AS-T120 after meal. Safety parameters will concurrently be measured.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TRK-100STP Pharmacokinetic Study in Healthy Volunteers - Evaluation of Pharmacokinetic Interaction Between TRK-100STP and Kremezin
Study Start Date : June 2008
Primary Completion Date : September 2008
Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions
U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1
Cross-over study
Other Names:
  • beraprost
  • Careload LA
Drug: AST-120 (Kremezin®)
Other Names:
  • Kremezin®
  • sopherical carbon adsorbent

Primary Outcome Measures :
  1. Pharmacokinetic profile [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. Safety parameters (vital signs, ECG, laboratory tests) [ Time Frame: 1 day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of written informed consent
  • Body Mass Index (BMI) of ≥17.6 to ≤26.4 kg/m2 and weight of ≥50 to ≤80 kg

Exclusion Criteria:

  • Clinical abnormal physical findings, including BP, pulse rate, ECG and laboratory assessments
  • Receives any investigational medicine within 120 days before screening
  • Recent blood donor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00719758

Tokyo, Japan, 108-8642
Sponsors and Collaborators
Astellas Pharma Inc
Toray Industries, Inc
Study Chair: Central Contact Astellas Pharma Inc

Responsible Party: Director, Astellas Pharma Inc.
ClinicalTrials.gov Identifier: NCT00719758     History of Changes
Other Study ID Numbers: 533-CL-005
First Posted: July 22, 2008    Key Record Dates
Last Update Posted: October 13, 2008
Last Verified: October 2008

Keywords provided by Astellas Pharma Inc:
beraprost sodium,
Careload LA
Spherical carbon adsorbent
Drug-drug interaction

Additional relevant MeSH terms:
Platelet Aggregation Inhibitors
Vasodilator Agents
Antihypertensive Agents